Details for New Drug Application (NDA): 210583
✉ Email this page to a colleague
The generic ingredient in ANJESO is meloxicam. There are twenty-two drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the meloxicam profile page.
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 30MG/ML (30MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Feb 20, 2020 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Feb 24, 2024 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Feb 24, 2024 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | May 26, 2030 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION |
Expired US Patents for NDA 210583
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Baudax | ANJESO | meloxicam | SOLUTION;INTRAVENOUS | 210583-001 | Feb 20, 2020 | ⤷ Sign Up | ⤷ Sign Up |
Baudax | ANJESO | meloxicam | SOLUTION;INTRAVENOUS | 210583-001 | Feb 20, 2020 | ⤷ Sign Up | ⤷ Sign Up |
Baudax | ANJESO | meloxicam | SOLUTION;INTRAVENOUS | 210583-001 | Feb 20, 2020 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription